Pheochromocytoma - Pipeline Review, H2 2017

Date: October 31, 2017
Pages: 92
Price:
US$ 2,000.00
License [?]:
Publisher: Global Markets Direct
Report type: Strategic Report
Delivery: E-mail Delivery (PDF)
ID: PFD4C088E8FEN
Leaflet:

Download PDF Leaflet

Pheochromocytoma - Pipeline Review, H2 2017
Pheochromocytoma - Pipeline Review, H2 2017

SUMMARY

Global Markets Direct's latest Pharmaceutical and Healthcare disease pipeline guide Pheochromocytoma - Pipeline Review, H2 2017, provides an overview of the Pheochromocytoma (Oncology) pipeline landscape.

Pheochromocytoma is a rare, usually non-cancerous (benign) tumor that develops in cells in the center of an adrenal gland. Symptoms include high blood pressure, severe headache, tremors, shortness of breath and constipation. Risk factors include multiple endocrine neoplasia type II (MEN), Von Hippel-Lindau disease (VHL) and neurofibromatosis 1 (NF1).

REPORT HIGHLIGHTS

Global Markets Direct's Pharmaceutical and Healthcare latest pipeline guide Pheochromocytoma - Pipeline Review, H2 2017, provides comprehensive information on the therapeutics under development for Pheochromocytoma (Oncology), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.

The Pheochromocytoma (Oncology) pipeline guide also reviews of key players involved in therapeutic development for Pheochromocytoma and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies/Universities/Institutes, the molecules developed by Companies in Phase II, Phase I and Preclinical stages are 7, 1 and 2 respectively. Similarly, the Universities portfolio in Discovery stages comprises 1 molecules, respectively.

Pheochromocytoma (Oncology) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from Global Markets Direct’s proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

Note: Certain content/sections in the pipeline guide may be removed or altered based on the availability and relevance of data.

SCOPE
  • The pipeline guide provides a snapshot of the global therapeutic landscape of Pheochromocytoma (Oncology).
  • The pipeline guide reviews pipeline therapeutics for Pheochromocytoma (Oncology) by companies and universities/research institutes based on information derived from company and industry-specific sources.
  • The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.
  • The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.
  • The pipeline guide reviews key companies involved in Pheochromocytoma (Oncology) therapeutics and enlists all their major and minor projects.
  • The pipeline guide evaluates Pheochromocytoma (Oncology) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type.
  • The pipeline guide encapsulates all the dormant and discontinued pipeline projects.
  • The pipeline guide reviews latest news related to pipeline therapeutics for Pheochromocytoma (Oncology)
REASONS TO BUY
  • Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.
  • Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.
  • Find and recognize significant and varied types of therapeutics under development for Pheochromocytoma (Oncology).
  • Classify potential new clients or partners in the target demographic.
  • Develop tactical initiatives by understanding the focus areas of leading companies.
  • Plan mergers and acquisitions meritoriously by identifying key players and it’s most promising pipeline therapeutics.
  • Formulate corrective measures for pipeline projects by understanding Pheochromocytoma (Oncology) pipeline depth and focus of Indication therapeutics.
  • Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
  • Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.
Introduction
Global Markets Direct Report Coverage
Pheochromocytoma - Overview
Pheochromocytoma - Therapeutics Development
Pipeline Overview
Pipeline by Companies
Pipeline by Universities/Institutes
Products under Development by Companies
Products under Development by Universities/Institutes
Pheochromocytoma - Therapeutics Assessment
Assessment by Target
Assessment by Mechanism of Action
Assessment by Route of Administration
Assessment by Molecule Type
Pheochromocytoma - Companies Involved in Therapeutics Development
Advanced Accelerator Applications SA
Exelixis Inc
Ipsen SA
Lixte Biotechnology Holdings Inc
Pfizer Inc
Progenics Pharmaceuticals Inc
Tarveda Therapeutics Inc
Valeant Pharmaceuticals International Inc
Pheochromocytoma - Drug Profiles
177Lu-Satoreotide - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
cabozantinib s-malate - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
iobenguane sulfate I 131 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
LB-100 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
LMP-400 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
lutetium Lu 177 dotatate - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
metyrosine - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
ONC-201 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
PEN-221 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
S-43126 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
sunitinib malate - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Pheochromocytoma - Dormant Projects
Pheochromocytoma - Product Development Milestones
Featured News & Press Releases
Oct 04, 2017: Data from Pivotal Phase 2b Study of Progenics’ AZEDRA (iobenguane I 131) to be Presented at the North American Neuroendocrine Tumor Society 2017 Annual Symposium
Aug 31, 2017: Progenics Pharmaceuticals Presents Data from AZEDRA Pivotal Phase 2b Study at the 5th International Symposium on Pheochromocytoma and Paraganglioma
Aug 31, 2017: Progenics Pharmaceuticals Provides Update on Timing of NDA Submission for AZEDRA
Mar 30, 2017: Progenics Pharmaceuticals Announces Positive Topline Results from Registrational Phase 2b Trial of AZEDRA
Jan 09, 2017: Advanced Accelerator Applications CEO Provides Progress Report on Corporate Developments of 2016; Asserts Confidence in Ability to Address FDA Comments on Lutathera NDA
Dec 03, 2015: Progenics Pharmaceuticals Achieves Target Enrollment in its Phase 2b Pivotal Trial of Azedra
Oct 12, 2015: Phase 2 Dosimetry Data for Progenics' AZEDRA Presented at EANM Congress 2015
Jul 28, 2015: Progenics Announces Breakthrough Therapy Designation for Azedra in Pheochromocytoma and Paraganglioma
Mar 02, 2015: Progenics Pharmaceuticals Announces Presentation at ENDO 2015
Jan 23, 2015: Progenics Pharmaceuticals Relaunches Pivotal Trial of AZEDRA in Pheochromocytoma
Sep 22, 2014: Progenics Pharmaceuticals Presents Long Term Follow-Up of Pivotal Phase 2 Trial of Azedra in Malignant Pheochromocytoma
Apr 01, 2014: Progenics Pharmaceuticals and Centre for Probe Development and Commercialization Announce Agreement to Manufacture Targeted Radiotherapeutic Candidate for Ultra-Orphan Indications
Nov 25, 2013: Progenics Pharmaceuticals Relaunching Registrational Trial of Azedra to Treat Pheochromocytomas
Appendix
Methodology
Coverage
Secondary Research
Primary Research
Expert Panel Validation
Contact Us
Disclaimer

LIST OF TABLES

Number of Products under Development for Pheochromocytoma, H2 2017
Number of Products under Development by Companies, H2 2017
Number of Products under Development by Universities/Institutes, H2 2017
Products under Development by Companies, H2 2017
Products under Development by Universities/Institutes, H2 2017
Number of Products by Stage and Target, H2 2017
Number of Products by Stage and Mechanism of Action, H2 2017
Number of Products by Stage and Route of Administration, H2 2017
Number of Products by Stage and Molecule Type, H2 2017
Pheochromocytoma - Pipeline by Advanced Accelerator Applications SA, H2 2017
Pheochromocytoma - Pipeline by Exelixis Inc, H2 2017
Pheochromocytoma - Pipeline by Ipsen SA, H2 2017
Pheochromocytoma - Pipeline by Lixte Biotechnology Holdings Inc, H2 2017
Pheochromocytoma - Pipeline by Pfizer Inc, H2 2017
Pheochromocytoma - Pipeline by Progenics Pharmaceuticals Inc, H2 2017
Pheochromocytoma - Pipeline by Tarveda Therapeutics Inc, H2 2017
Pheochromocytoma - Pipeline by Valeant Pharmaceuticals International Inc, H2 2017
Pheochromocytoma - Dormant Projects, H2 2017

LIST OF FIGURES

Number of Products under Development for Pheochromocytoma, H2 2017
Number of Products under Development by Companies, H2 2017
Number of Products by Top 10 Targets, H2 2017
Number of Products by Stage and Top 10 Targets, H2 2017
Number of Products by Top 10 Mechanism of Actions, H2 2017
Number of Products by Stage and Top 10 Mechanism of Actions, H2 2017
Number of Products by Routes of Administration, H2 2017
Number of Products by Stage and Routes of Administration, H2 2017
Number of Products by Molecule Types, H2 2017
Number of Products by Stage and Molecule Types, H2 2017

COMPANIES MENTIONED

Advanced Accelerator Applications SA
Exelixis Inc
Ipsen SA
Lixte Biotechnology Holdings Inc
Pfizer Inc
Progenics Pharmaceuticals Inc
Tarveda Therapeutics Inc
Valeant Pharmaceuticals International Inc
Skip to top


Ask Your Question

Pheochromocytoma - Pipeline Review, H2 2017
Company name*:
Contact person*:
Phone/fax*:
Email*:
Request invoice
Your enquiry:
Please click on a Check Box below to confirm you are not a robot: